Loading
ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes.
CIViC holds 1 clinical evidence item and 0 assertions across 2 variants. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.00, somatic mutation 0.98). IntOGen calls it a driver in 36 cohorts (3 activating, 33 loss-of-function), covering Cholangiocarcinoma, Cutaneous Squamous Cell Carcinoma, Oesophageal Adenocarcinoma, Oesophageal Squamous Cell Carcinoma, Glioblastoma, Gallbladder Cancer and others.
In plain words · ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.
ARID2 (AT-rich interactive domain-containing protein 2) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Hepatocellular carcinoma, Oesophageal cancer and 5 more.
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF).
No product in this corpus aims at ARID2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA ARID2: RNA low tissue specificity; no normal tissue stained high. Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Skin cancer (all types), Hepatocellular carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer, Biliary tract cancer (all types), Head and neck squamous cell carcinoma, Nasopharyngeal carcinoma and more); Open Targets associates it with 2 specific cancer types at or above 0.5 (hepatocellular carcinoma, melanoma). (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q68CP9; CIViC gene ARID2; IntOGen ARID2; Human Protein Atlas ARID2 tissue; Open Targets ENSG00000189079 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Nagase et al, DNA Res, 2000, "Prediction of the coding sequences of unidentified human genes. XVIII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro". Source.
Sources: HGNC HGNC:18037 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q68CP9 (protein name, function text, keywords and locations (REST API)); CIViC gene ARID2 (1 evidence items, 0 assertions, 2 variants; diseases: Hepatocellular Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000189079 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.53, oesophageal cancer 0.57, hepatocellular carcinoma 0.63, melanoma 0.72, skin cancer 0.67, lung cancer 0.51 (GraphQL API, CC0)); IntOGen ARID2 (driver in 36 cohorts (Act 3, LoF 33); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Involved in transcriptional activation and repression of select genes by chromatin remodeling (alteration of DNA-nucleosome topology). Required for the stability of the SWI/SNF chromatin remodeling complex SWI/SNF-B (PBAF). May be involved in targeting the complex to different genes. May be involved in regulating transcriptional activation of cardiac genes. Location: Nucleus (UniProt). Locus 12q12 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ARID2" OR ABSTRACT:"ARID2" OR TITLE:"AT-rich interaction domain 2" OR ABSTRACT:"AT-rich interaction domain 2" OR TITLE:"AT-rich interactive domain-containing protein 2" OR ABSTRACT:"AT-rich interactive domain-containing protein 2" OR TITLE:"KIAA1557" OR ABSTRACT:"KIAA1557" OR TITLE:"DKFZp686G052" OR ABSTRACT:"DKFZp686G052" OR TITLE:"FLJ30619" OR ABSTRACT:"FLJ30619") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ARID2, not a curated reading list.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), Hepatocellular carcinoma.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), CIViC.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), Hepatocellular carcinoma, CIViC.
Shares Nasopharyngeal carcinoma, Oesophageal cancer, Skin cancer (all types), Hepatocellular carcinoma.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), Hepatocellular carcinoma.
Shares Nasopharyngeal carcinoma, Skin cancer (all types), CIViC, IntOGen.
Shares Biliary tract cancer (all types), Hepatocellular carcinoma, CIViC, IntOGen.
Shares Biliary tract cancer (all types), Oesophageal cancer, Skin cancer (all types), CIViC.